ArticleClinical oral investigations2017
Opiorphin levels in fluids of burning mouth syndrome patients: a case-control study.
Article in Clinical oral investigations, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research of a Biological Marker for Chronic Orofacial Pain: Dosage of Opiorphin in Patients With Burning Mouth Syndrome
Salivary Immune/Stress Biomarkers Among Children
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Exploring the association between menopause and burning mouth syndrome: an updated review.BMC oral health · 2026Pooled it
- Opiorphin as a biomarker of orofacial conditions: a meta-analysis.Scientific reports · 2023Pooled it
- Neuropathic and Psychogenic Components of Burning Mouth Syndrome: A Systematic Review.Biomolecules · 2021Pooled it
- Association of Vitamin B6 and Homocysteine-ACTH Coupling With Depressive and Anxiety Symptoms in Burning Mouth Syndrome: An Exploratory Case-Control Study.Journal of oral rehabilitation · 2026Article
- Salivary opiorphin as a potential non-invasive biomarker for dental anxiety.BMC oral health · 2026Article
- Psychological factors and salivary biomarkers (cortisol and opiorphin) in erosive oral lichen planus: A case-control study.Journal of dental research, dental clinics, dental prospects · 2025Article
- Comparison of Salivary Opiorphin in Burning Mouth Syndrome and Healthy Subjects and Its Correlation With Psychiatric Disorders.Clinical and experimental dental research · 2024Article
- Time-course of pain and salivary opiorphin release in response to oral capsaicin differ in burning mouth syndrome patients, temporomandibular disorders patients and control subjects.Clinical oral investigations · 2024Observational
- Evaluation of Salivary Opiorphin, pH and Flow Rate in Oral Submucous Fibrosis - A Case - Control Observational Study.Journal of pharmacy & bioallied sciences · 2023Article
- A possible alternative to Opiorphin and its stable analogues for treating fibromyalgia pain: A clinical hypothesis.Northern clinics of Istanbul · 2023Review
- Expression of salivary immunoglobulins and their association with analgesic neuropeptide opiorphin in anorexia nervosa during adolescence.Journal of eating disorders · 2022Article
- Role of opiorphin genes in prostate cancer growth and progression.Future oncology (London, England) · 2021Article
- Critical role of mass spectrometry proteomics in tear biomarker discovery for multifactorial ocular diseases (Review).International journal of molecular medicine · 2021Review
- Salivary Biomarkers (Opiorphin, Cortisol, Amylase, and IgA) Related to Age, Sex, and Stress Perception in a Prospective Cohort of Healthy Schoolchildren.Mediators of inflammation · 2021Article
- Biomarkers in orofacial pain conditions: A narrative review.Journal of oral biology and craniofacial researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesIdiopathic Burning mouth syndrome (iBMS) is a poorly understood affection characterized by persistent pain in the oral cavity without any clinical or biological abnormality. Opiorphin is a natural inhibitor of enkephalin-inactivating ectopeptidases, mainly produced by salivary glands, that has demonstrated analgesic properties. The objective of the present case-control study was to test the hypothesis of a decrease in opiorphin levels in iBMS patients. MATERIALS AND
methodsTwenty-one iBMS patients and 21 matched controls subjects were included between 2011 and 2013. Submandibular and sublingual salivary, blood, and urinary opiorphin levels of iBMS patients were compared to controls.
resultsResults are expressed as mean values ± SD and compared using the Wilcoxon Signed Rank test. Correlations were analyzed with Spearman coefficient. The level of significance was fixed at p < 0.05. Opiorphin levels in iBMS and controls were respectively (in ng/ml) in basal saliva: 37.8 ± 42.5 and 67.6 ± 188.9 (p = NS); stimulated saliva: 28.8 ± 25.3 and 31.1 ± 29.1 (p = NS); blood: 4.6 ± 5.4 and 1.9 ± 1.4 (p < 0.05); and urines: 68.5 ± 259.8 and 8.9 ± 6.2 (p = NS). CLINICAL RELEVANCE: In conclusion, the lack of significative difference in salivary opiorphin levels between iBMS and controls does not favor a direct local role for opiorphin in the etiopathogeny of iBMS. However, higher blood opiorphin levels may reflect a systemic dysregulation in iBMS. Trial registration NCT02686359 https://clinicaltrials.gov/ct2/show/NCT02686359.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.